Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

High-density lipoproteins: marker of cardiovascular risk and therapeutic target.

Toth PP, Davidson MH.

J Clin Lipidol. 2010 Sep-Oct;4(5):359-64. doi: 10.1016/j.jacl.2010.08.002. Epub 2010 Aug 17.

PMID:
21122679
2.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
3.

Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.

Walldius G, Jungner I.

Curr Opin Cardiol. 2007 Jul;22(4):359-67. Review.

PMID:
17556890
4.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
5.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
6.
7.

The rationale for using apoA-I as a clinical marker of cardiovascular risk.

Barter PJ, Rye KA.

J Intern Med. 2006 May;259(5):447-54. Review.

8.

Managing the risk of atherosclerosis: the role of high-density lipoprotein.

Libby P.

Am J Cardiol. 2001 Dec 20;88(12A):3N-8N. Review.

PMID:
11788123
9.

High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.

Toth PP.

Am J Cardiol. 2005 Nov 7;96(9A):50K-58K; discussion 34K-35K. Epub 2005 Sep 15. Review.

PMID:
16291015
10.

Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.

Toth PP, Davidson MH.

Curr Opin Cardiol. 2004 Jul;19(4):374-9. Review.

PMID:
15218399
11.

High-density lipoprotein metabolism: potential therapeutic targets.

Davidson MH, Toth PP.

Am J Cardiol. 2007 Dec 3;100(11 A):n32-40. Review.

PMID:
18047851
12.

Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.

Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ.

Curr Opin Cardiol. 2003 Jul;18(4):286-94. Review.

PMID:
12858127
13.

High-density lipoproteins: multifunctional vanguards of the cardiovascular system.

Marcil M, O'Connell B, Krimbou L, Genest J Jr.

Expert Rev Cardiovasc Ther. 2004 May;2(3):417-30. Review.

PMID:
15151487
14.

High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease.

Rohrer L, Hersberger M, von Eckardstein A.

Curr Opin Lipidol. 2004 Jun;15(3):269-78. Review.

PMID:
15166782
15.
16.

Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.

Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J; HDL Forum.

Am J Cardiovasc Drugs. 2004;4(5):299-314. Review.

PMID:
15449972
17.

High-density lipoproteins: an emerging target in the prevention of cardiovascular disease.

Cutri BA, Hime NJ, Nicholls SJ.

Cell Res. 2006 Oct;16(10):799-808. Review.

18.

High-density lipoproteins and cardiovascular disease: 2010 update.

Alwaili K, Awan Z, Alshahrani A, Genest J.

Expert Rev Cardiovasc Ther. 2010 Mar;8(3):413-23. doi: 10.1586/erc.10.4. Review.

PMID:
20222819
19.

Should we target HDL cholesterol level in lowering cardiovascular risk?

Toth PP.

Pol Arch Med Wewn. 2009 Oct;119(10):667-72. Review.

20.

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.

Chapman MJ.

Pharmacol Ther. 2006 Sep;111(3):893-908. Epub 2006 Mar 29. Review.

PMID:
16574234

Supplemental Content

Support Center